Health
Eli Lilly tests dual amylin and tirzepatide therapy for obesity
CNBC reports Eli Lilly saw enhanced weight loss combining eloralintide with tirzepatide, alongside higher side-effect discontinuations.
The short version
- Eli Lilly evaluated its experimental amylin-targeting drug eloralintide alongside tirzepatide in a Phase 2 trial for patients with obesity and Type 2 diabetes.[CNBC]
- Patients receiving the highest combined dose achieved an average 23.3% weight loss over 48 weeks, compared to 14.8% for tirzepatide alone.[CNBC]
- Treatment dropouts due to side effects ranged from 10.8% to 27% in the combined therapy groups, versus 2.9% for tirzepatide alone.[CNBC]
- Phase 3 clinical trials intended to confirm the Phase 2 findings are scheduled to launch later this year.[CNBC]
Key facts
- In a Phase 2 trial, patients on the highest-dose combination of eloralintide and tirzepatide averaged 23.3% weight loss at 48 weeks compared to 14.8% on tirzepatide alone.[CNBC]
- Between 10.8% and 27% of combination trial participants discontinued treatment due to adverse side effects, compared with 2.9% receiving tirzepatide alone.[CNBC]
- Phase 3 clinical trials to confirm the Phase 2 results are scheduled to begin later in the year.[CNBC]
- Analyst David Risinger of Leerink Partners projects annual sales of eloralintide products will reach $23.2 billion by the end of 2035.[CNBC]
What remains uncertain
- The Phase 2 study was relatively small, leaving final efficacy and tolerability to be verified in upcoming Phase 3 trials.[CNBC]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.